

Pneumovax® 23 Standing Order

Issue date:		Review date:	
--------------------	--	---------------------	--

This standing order is not valid after the review date. The review date is one year after the date the order was signed by the issuer.

Standing Order Name	Pneumovax® 23
Rationale	To prevent pneumococcal disease in patients on immunosuppressive therapy.
Scope (condition and patient group)	Adult patients who are on immunosuppressive therapy who are at high risk of pneumococcal disease. The recommendation is that Prevenar 13® should be given as the first vaccine (see separate standing order). This standing order covers the first dose, and a second dose of Pneumovax® 23, five years after the first dose.
Red Flags	If a patient has had Prevenar 13® then at least 8 weeks needs to lapse before Pneumovax® 23 can be given.
Assessment	Review patient to ensure they are due for this vaccination. Advise patient that this is a non-funded vaccination for this indication. The vaccination is due to be given as per the current on-line version of the National Immunisation Schedule
Indication	Adult patients whom <ul style="list-style-type: none"> • Are on immunosuppressant therapy • The vaccine is scheduled • Informed consent has been obtained.
Medicine	Pneumovax® 23
Dosage instructions	Intramuscularly inject 0.5mLs into the deltoid muscle
Route of administration	Intramuscular
Quantity to be given	1 x 0.5mL injection
Contraindications	Anyone with severe allergy (anaphylaxis) to a previous dose of this vaccine or a component of the vaccine.
Precautions	<ul style="list-style-type: none"> • Severe/acute illness with a fever over 38°C. The presence of a minor infection is not a reason to delay immunisation.
Additional information	Appropriate medical treatment and supervision should be available in the event of an anaphylactic reaction. Adrenaline should always be available when Pneumovax® 23 is given. Pneumovax® 23 can be administered at the same time as the annual influenza vaccination. A booster dose of Pneumovax® 23 is recommended 5 years after the initial dose Prevenar 13® Should be offered as the first vaccination. However if a patient can not afford Prevenar 13®, then Pneumovax® 23 can be offered. If however the patient has already received Pneumovax® 23, then at least a year must separate Pneumovax® 23 and Prevenar 13® (if given in this order)
Follow-up	Advise patient to seek further medical treatment if injection site becomes red, inflamed or severe pain.
Countersigning and auditing	Countersigning is not required. Audited monthly. OR Countersigning is required within XX days

Competency/training requirements	All nurses working under this standing order must be signed off as competent to do so by the issuer and have had specific training in this standing order. Nurses must have completed approved vaccinator training and ongoing two year updates. Nurses must be approved independent vaccinators and be competent in vaccination delivery, contraindications and cold chain protocol.
Supporting documentation	Healthpathways at www.healthpathways.org.nz Individual medicine data sheets at www.medsafe.govt.nz Standing Order Guidelines, Ministry of Health, 2012 Immunisation Handbook 2014. www.immune.org.nz
Definition of terms used in standing order	Pneumovax® 23 - is a vaccine which has been shown to produce antibodies to the 23 most prevalent or invasive pneumococcal-types

Medical Centre or Clinic:	
----------------------------------	--

Signed by issuers

Name: _____

Signature: _____

Title: _____

Date: _____

Nurses operating under this standing order

Only Registered nurses working within the above medical centre or clinic are authorised to administer medication under this standing order.

We the undersigned agree that we have read, understood and will comply with this standing order and all associated documents.

Name: _____ Signature: _____ Date: _____

Name: _____ Signature: _____ Date: _____

Name: _____ Signature: _____ Date: _____

Name: _____ Signature: _____ Date: _____